<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845364</url>
  </required_header>
  <id_info>
    <org_study_id>RRK3217</org_study_id>
    <secondary_id>Eudract 2006-003164-62</secondary_id>
    <secondary_id>REC 06/Q0104/141</secondary_id>
    <secondary_id>BHF PG/06/044/20703</secondary_id>
    <nct_id>NCT00845364</nct_id>
  </id_info>
  <brief_title>Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery</brief_title>
  <acronym>CASPER</acronym>
  <official_title>Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-heart surgery causes injury of the heart muscle. Although this is usually mild,
      temporary and reversible, if it is severe it can endanger life and require additional high
      cost care. During surgery, techniques are used to protect the heart from injury, but these
      remain imperfect. This study assesses the effect of facilitating sugar metabolism (a more
      efficient fuel) by the heart muscle using the drug Perhexiline given before the operation.
      This treatment has a sound experimental basis for improving outcome. If this improvement is
      confirmed surgical results could be improved. The investigators will be studying heart
      function, heart muscle energy stores and chemicals which quantify the amount of heart muscle
      injury. The investigators' hypothesis is that Perhexiline will improve the protection of the
      heart by decreasing damage that may occur during heart surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Low Cardiac Output Syndrome</measure>
    <time_frame>6 hours post-removal of aortic X-clamp</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Cardiac index of greater than or equal to 0.3 L/min/m2</measure>
    <time_frame>6 hours post-removal of aortic X-clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of inotropes use according to protocol</measure>
    <time_frame>6 and 12 hours post-removal of aortic X-clamp</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak and total release of Troponin</measure>
    <time_frame>6, 12 and 24 hours post-release of aortic X-clamp</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Myocardial Reperfusion Injury</condition>
  <condition>Cardiac Output, Low</condition>
  <arm_group>
    <arm_group_label>Perhexiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative administration of Perhexiline tablets according to dosing schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-operative administration of placebo tablets according to dosing schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perhexiline</intervention_name>
    <description>Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.</description>
    <arm_group_label>Perhexiline</arm_group_label>
    <other_name>PEXSIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo marked PEXSIG</intervention_name>
    <description>Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  First-time

          -  Isolated coronary artery bypass surgery

        Exclusion Criteria:

          -  Diabetes Mellitus

          -  Renal impairment with Creatinine greater than or equal to 200micromol/L

          -  Atrial fibrillation

          -  Amiodarone therapy, recent (in last month) or current

          -  Hepatic impairment, significant preoperative

          -  Peripheral neuropathy

          -  Pregnancy or breast-feeding

          -  Emergency surgery or required on clinical grounds within 5 days of referral
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domeinco Pagano, MD FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <state>West Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Quinn DW, Pagano D, Bonser RS, Rooney SJ, Graham TR, Wilson IC, Keogh BE, Townend JN, Lewis ME, Nightingale P; Study Investigators. Improved myocardial protection during coronary artery surgery with glucose-insulin-potassium: a randomized controlled trial. J Thorac Cardiovasc Surg. 2006 Jan;131(1):34-42.</citation>
    <PMID>16399292</PMID>
  </reference>
  <reference>
    <citation>Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, Keogh BE, Mascaro J, Riddington DW, Rooney SJ, Townend JN, Wilson IC, Bonser RS. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation. 2006 Jul 4;114(1 Suppl):I245-50.</citation>
    <PMID>16820580</PMID>
  </reference>
  <reference>
    <citation>Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97. Review.</citation>
    <PMID>17445089</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>May 19, 2010</last_update_submitted>
  <last_update_submitted_qc>May 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr Domenico Pagano</name_title>
    <organization>University Hospital Birmingham</organization>
  </responsible_party>
  <keyword>Perhexiline</keyword>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Myocardial reperfusion injury</keyword>
  <keyword>Cardiac output, low</keyword>
  <keyword>Troponin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
    <mesh_term>Cardiac Output, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perhexiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

